Ascendis Pharma A (ASND) Depreciation & Amortization (CF) (2014 - 2026)

Ascendis Pharma A has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $4.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 3.34% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 5.28% YoY) and the FY2025 annual result came in at $20.0 million, up 8.67% from the prior year.
• Depreciation & Amortization (CF) retreated to $4.9 million in Q1 2026 per ASND's latest filing, from $5.5 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.5 million in Q4 2025 and troughed at $4.4 million in Q3 2022.
• A 5-year average of $4.8 million and a median of $4.7 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) retreated 10.37% in 2024, then advanced 17.41% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $4.6 million in 2022, then gained by 12.47% to $5.2 million in 2023, then dropped by 10.37% to $4.7 million in 2024, then grew by 17.41% to $5.5 million in 2025, then dropped by 9.6% to $4.9 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.9 million, $5.5 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.